Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Clinical Research

Response monitoring with DCE-MRI, H215O-PET and 18FDG-PET in patients with advanced NSCLC treated with bevacizumab and erlotinib

A.j. de Langen, V.E.M. van den Boogaart, A.C. Dingemans, O.s. Hoekstra, H.J.M. Groen, B. Brans, J. Pruim, M. Lubberink, P. Kappert and E.f. Smit
A.j. de Langen
VU University Medical Center, Amsterdam, Netherlands, University Hospital Maastricht, Maastricht, Netherlands, University Medical Center Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V.E.M. van den Boogaart
VU University Medical Center, Amsterdam, Netherlands, University Hospital Maastricht, Maastricht, Netherlands, University Medical Center Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.C. Dingemans
VU University Medical Center, Amsterdam, Netherlands, University Hospital Maastricht, Maastricht, Netherlands, University Medical Center Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O.s. Hoekstra
VU University Medical Center, Amsterdam, Netherlands, University Hospital Maastricht, Maastricht, Netherlands, University Medical Center Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.J.M. Groen
VU University Medical Center, Amsterdam, Netherlands, University Hospital Maastricht, Maastricht, Netherlands, University Medical Center Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Brans
VU University Medical Center, Amsterdam, Netherlands, University Hospital Maastricht, Maastricht, Netherlands, University Medical Center Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Pruim
VU University Medical Center, Amsterdam, Netherlands, University Hospital Maastricht, Maastricht, Netherlands, University Medical Center Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Lubberink
VU University Medical Center, Amsterdam, Netherlands, University Hospital Maastricht, Maastricht, Netherlands, University Medical Center Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Kappert
VU University Medical Center, Amsterdam, Netherlands, University Hospital Maastricht, Maastricht, Netherlands, University Medical Center Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E.f. Smit
VU University Medical Center, Amsterdam, Netherlands, University Hospital Maastricht, Maastricht, Netherlands, University Medical Center Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2008
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

Abstract

3638

Background:
Efficacy of targeted drugs by RECIST criteria may underestimate their clinical value. The aim of the current study was to evaluate whether early response to treatment with bevacizumab and erlotinib in patients with advanced NSCLC can be assessed with 18FDG-PET, H215O-PET and DCE-MRI.
Methods:
In a multicenter phase II study, chemonaive patients with advanced non-squamous NSCLC were treated with bevacizumab 15 mg/kg q 3 week and erlotinib 150 mg daily until progression. Primary endpoint was non-progression rate (NPR) at 6 weeks posttreatment.
Patients underwent dynamic 18FDG-PET, H215O-PET and CE-MRI scanning as well as CT at baseline and after 3 and 6 weeks of treatment.
RECIST measurements at CT, standard uptake value (SUV) at 18FDG-PET, tumor perfusion (F) at H215O-PET and the endothelial transfer constant (Kps) at DCE-MRI were defined at each time point.
Results:
A total number of 44 patients were included. NPR after 6 weeks was 75%.
At baseline and after 3 weeks of treatment complete data sets were available for 15 patients. H215O-PET, 18FDG-PET and DCE-MRI data at both baseline and after 3 weeks were available for 19, 32 and 29 patients, respectively.
Results for all patients: M/F 22/22; median age 59 (range 34-80); stage IIIB/IV 9/35; PS 0/1/2: 21/18/5. At the time of analysis 32/44 patients have died and 40/44 progressed. Median time to follow up was 462 days, median time to progression 92 days and median survival 209 days.
Radiological response by RECIST after 3 weeks of treatment (stable disease/partial response vs. progressive disease) did not significantly correlate with survival (p=0.1) and showed borderline significance after 6 weeks of treatment (p=0.048).
Kpsshowed a median decrease of 32% (IQR -60% to +26%) after 3 weeks (p=0.09), but did not correlate with TTP and overall survival (p=0.5, p=0.9).
Residual SUV and F after 3 weeks of treatment predicted TTP (p=0.001, p=0.029) and survival (p=0.02, p=0.039).
At baseline and after treatment, no significant correlations were found between MRI derived parameter Kps and PET derived parameters F and SUV, as well as between SUV and F (pearson correlation coefficient, p>0.1).
Conclusion:
18FDG-PET and H215O-PET seem valuable biomarkers in monitoring early response to antiangiogenic treatment in patients with NSCLC.
DCE-MRI derived Kps reflected treatment effect, but was not predictive of patient outcome.
The lack of correlation between glucose metabolism and perfusion, as measured with PET, indicates that both have independent prognostic value. Multivariate analysis can only be done in a larger sample. Therefore, these results should be confirmed in a prospective study.

Footnotes

  • 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 68 (9 Supplement)
May 2008
Volume 68, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Response monitoring with DCE-MRI, H215O-PET and 18FDG-PET in patients with advanced NSCLC treated with bevacizumab and erlotinib
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Response monitoring with DCE-MRI, H215O-PET and 18FDG-PET in patients with advanced NSCLC treated with bevacizumab and erlotinib
A.j. de Langen, V.E.M. van den Boogaart, A.C. Dingemans, O.s. Hoekstra, H.J.M. Groen, B. Brans, J. Pruim, M. Lubberink, P. Kappert and E.f. Smit
Cancer Res May 1 2008 (68) (9 Supplement) 3638;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Response monitoring with DCE-MRI, H215O-PET and 18FDG-PET in patients with advanced NSCLC treated with bevacizumab and erlotinib
A.j. de Langen, V.E.M. van den Boogaart, A.C. Dingemans, O.s. Hoekstra, H.J.M. Groen, B. Brans, J. Pruim, M. Lubberink, P. Kappert and E.f. Smit
Cancer Res May 1 2008 (68) (9 Supplement) 3638;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Research

  • Abstract SY20-03: Novel radiotracers for clinical molecular imaging in oncology
  • Abstract PL01-02: The Breast International Group (BIG): Building on an accelerated path to tailored adjuvant cancer therapy
  • Abstract SS02-04: How much can we afford to pay for new drugs, and how do we make those decisions?
Show more 3

Molecular Predictors of Drug Sensitivity and Resistance: Poster Presentations - Proffered Abstracts

  • Topoisomerase I expression in rectal cancer correlates to response rate to preoperative chemoradiation
  • Epithelial mesenchymal transition is a determinant of sensitivity to the EGFR inhibitor erlotinib in triple negative breast tumors
  • Low expression of thymidylate synthase and dihydropyrimidine dehydrogenase is associated with better response to capecitabine-based chemotherapy in patients with advanced colorectal cancer, but with limited predictive value
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement